- Ọgwụgwọ
- Akaebe
- Neuroblastoma
- Tumor siri ike
- Akaebe
- TILS
- NK Cell Therapy
- Myasthenia Gravis (MG)
- Nnukwu ọrịa leukemia Lymphoblastic (B-ALL)
- Lupus Erythematosus System (SLE)
- Nnukwu ọrịa leukemia Lymphoblastic (T-ALL)
- Na-abụghị Hodgkin Lymphoma (NHL)
- Multiple Myeloma (MM)
- Na-ekesa nnukwu Lymphom B-cell
- B-lymphocytic leukemia
- Myeloma
CAR-T maka nnukwu B-cell Lymphoblastic leukemia (B-ALL)
Nchịkọta
B-ALL (Acute B-cell Lymphoblastic leukemia) bụ ụdị ọrịa leukemia na-eme ihe ike, nke na-emetụta ụmụaka na ndị okenye. N'agbanyeghị ọganihu na ọgwụgwọ chemotherapy ọdịnala, ọtụtụ ndị ọrịa na-enweta nlọghachi azụ ma ọ bụ nkwụsị ọgwụgwọ. CAR-T (Chimeric Antigen Receptor T-cell) ọgwụgwọ na-anọchite anya immunotherapy na-emebi emebi nke gosipụtara ihe ịga nke ọma dị ịrịba ama n'ịgwọ nlọghachi azụ ma ọ bụ B-ALL, na-enye olileanya maka ndị ọrịa na-enwebu oke nhọrọ ọgwụgwọ.
Kedu ihe bụ CAR-T Therapy?
Usoro ọgwụgwọ CAR-T bụ ọgwụgwọ dị elu, ahaziri onwe ya nke gụnyere imegharị mkpụrụ ndụ T nke onye ọrịa iji mata ma wakpo mkpụrụ ndụ kansa ọgụ. Maka B-ALL, a na-emezi mkpụrụ ndụ CAR-T ka ha lekwasị anya na CD19 antigen, protein a na-ahụkarị n'elu sel B-cell leukemia. Ozugbo etinyere ya n'ime ahụ onye ọrịa ahụ, mkpụrụ ndụ T ndị a na-emezigharị na-achọ ma bibie mkpụrụ ndụ leukemia, nke nwere ike ibute mgbaghara na-adịte aka.
Isi uru nke ọgwụgwọ CAR-T maka B-ALL
- Ịrụ ọrụ dị elu: Usoro ọgwụgwọ CAR-T egosila nnukwu ihe ịga nke ọma n'ịgwọ nlọghachi azụ ma ọ bụ refractory B-ALL, na-enye ọnụ ọgụgụ dị elu nke mgbapụta na ndị ọrịa na-anabataghị ọgwụgwọ ọdịnala.
- Omume ezubere iche: Site n'ilekwasị anya na antigen CD19, ọgwụgwọ CAR-T na-elekwasị anya ma na-ebibi mkpụrụ ndụ B-ALL, na-ebelata mmebi nke anụ ahụ dị mma.
- Ọgwụgwọ ahaziri onwe ya: Ebe ọ bụ na mkpụrụ ndụ CAR-T na-enweta site na usoro ahụ ji alụso ọrịa ọgụ nke onye ọrịa, a na-ahazi ọgwụgwọ ahụ nke ọma, na-abawanye uru ya na ibelata ihe ize ndụ nke ịjụ.
- Mgbaghara na-adịgide adịgide: N'ọtụtụ ọnọdụ, ọgwụgwọ CAR-T emela ka mgbaghara na-adịgide adịgide, na-enye ndị ọrịa ohere ịlanarị ogologo oge na nlọghachi ole na ole.
Usoro ọgwụgwọ
- Nchịkọta nke cell TNzọụkwụ mbụ gụnyere ịnakọta mkpụrụ ndụ T n'ọbara onye ọrịa site na usoro a na-akpọ leukapheresis.
- Injinia T-cell: A na-emezi mkpụrụ ndụ T nke anakọtara na ụlọ nyocha iji gosipụta chimeric antigen receptor (CAR) kpọmkwem na CD19, na-eme ka ikike ha na-elekwasị anya na sel B-ALL.
- Infusion nke mkpụrụ ndụ CAR-T: Mgbe obere oge nke mgbasawanye cell gachara, a na-agbanyeghachi mkpụrụ ndụ CAR-T n'ime ahụ onye ọrịa site na intravenous (IV).
- Nleba anya na mgbake: Post-infusion, a na-enyocha ndị ọrịa nke ọma maka mmetụta ndị nwere ike ime dị ka cytokine release syndrome (CRS) na neurotoxicity. Mmeghachi omume ndị a na-adịkarị mfe ijikwa, na ọtụtụ ndị ọrịa na-agbake site na enyemaka kwesịrị ekwesị.
Kedu ihe kpatara ịhọrọ ọgwụgwọ BIOOCUS CAR-T maka B-ALL?
- Teknụzụ ọgbara ọhụrụBIOOCUS na-eji teknụzụ na-egbutu ọnụ iji hụ na mmepụta mkpụrụ ndụ CAR-T kacha mma yana nsonaazụ onye ọrịa.
- Otu ọkachamara ahụike: Ndị otu anyị ndị ọkachamara na hematology na immunotherapy raara onwe ha nye inye nlekọta ahaziri onwe ya na ịkwalite ọganihu nke ọgwụgwọ ọ bụla.
- Ahụmahụ mba ụwa: Anyị na-enye ndị ọrịa si gburugburu ụwa ọgwụgwọ CAR-T, yana ndekọ ndekọ nke ọgwụgwọ na-aga nke ọma na mgbapụta ogologo oge maka ndị ọrịa B-ALL.
- Nlekọta zuru oke: Site na nyocha mbụ site na nlekota nlekota, BIOOCUS na-enye nlekọta zuru oke, na-eme ka ndị ọrịa nweta ọgwụgwọ kachasị mma n'oge ọ bụla.
Ihe akaebe na-ahụ maka ụlọ ọgwụ na ọnụego ihe ịga nke ọma
Nnwale ụlọ ọgwụ na nso nso a na data ụwa n'ezie egosila na ọgwụgwọ CAR-T maka B-ALL na-enye nsonaazụ pụrụ iche, ọkachasị maka ndị ọrịa laghachiri azụ ma ọ bụ na-eguzogide ọgwụgwọ ọdịnala. Usoro ọgwụgwọ ahụ egosipụtala ọnụ ọgụgụ mgbaghara dị elu mgbe niile, yana ọtụtụ ndị ọrịa na-enweta mgbaghara zuru oke na ịnọgide na-adị ogologo oge.
Na BIOOCUS, anyị ejirila ọgwụgwọ CAR-T gwọọ ọtụtụ ndị ọrịa nwere B-ALL nke ọma, nsonaazụ ya adịla mma nke ukwuu. Maka nghọta miri emi nke akụkọ ịga nke ọma na nsonaazụ ndụ n'ezie, biko nyochaa ihe ọmụmụ ndị ọrịa ndị a:
- Akụkọ onye ọrịa: B-ALL nwere ihe ize ndụ dị elu, ntụgharị ụmị ọkpụkpụ n'ime ọnwa 9-afọ abụọ ka e mesịrị, Mmalite ahụike
- Site na ọdịda mbido mbụ ruo na mgbake zuru oke: Njem onye ọrịa na Lu Daopei's Advanced Transplant
- Nnukwu ọrịa leukemia Lymphoblastic (B-ALL) Ozi ngwaahịa na ọmụmụ ihe
Ọnọdụ ndị a na-egosipụta ikike mgbanwe nke ọgwụgwọ CAR-T maka ndị ọrịa B-NIILE, na-egosi ọ bụghị naanị ịdị irè ọgwụgwọ kamakwa ikike ya inye ndị ọrịa ohere nke abụọ na ndụ.
Data ụlọ ọgwụ
Ngosipụta maka CD19+20CAR-T:Ndị ọrịa nwere lymphoma na-abụghị Hodgkin B-cell
| Ọnụego otu ọnwa CR | Ọnụego PR otu ọnwa | Otu ọnwa ma ọ bụ ọnụego | CRS≥3 | CRES≥3 |
| 71.95% (59/82) | 25.6 (21/82) | 97.55 (80/82) | 12.19% (10/82) | 0 |
Ngosipụta maka CD19+22CAR-T:Ọgwụgwọ nke CD19 nlọghachite na refractory nnukwu B-lymphocytic leukemia ndị ọrịa.
| Ọnụego otu ọnwa CR | Ọnụego PR otu ọnwa | Otu ọnwa ma ọ bụ ọnụego | CRS≥3 | CRES≥3 |
| 92.1% (35/38) | 7.9% (3/38) | 100% (38/38) | 15.79% (6/38) | 0 |
Ngosipụta maka BCMACAR-T:Ọgwụgwọ nke nlọghachi azụ na refractory multiple myeloma
| Ọnụego otu ọnwa CR | Ọnụego PR otu ọnwa | Otu ọnwa ma ọ bụ ọnụego | CRS≥3 | CRES≥3 |
| 72.41% (21/29) | 27.59% (8/29) | 100% (29/29) | 6.9% (2/29) | 0 |
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.




